Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9 by Muhammad Riaz et al.
RESEARCH Open Access
Differential myofiber-type transduction
preference of adeno-associated virus
serotypes 6 and 9
Muhammad Riaz1*, Yotam Raz1, Elizabeth B. Moloney2, Maaike van Putten1, Yvonne D. Krom1,
Silvere M. van der Maarel1, Joost Verhaagen2,3 and Vered Raz1
Abstract
Background: Gene therapy strategies are promising therapeutic options for monogenic muscular dystrophies, with
several currently underways. The adeno-associated viral (AAV) vector is among the most effective gene delivery
systems. However, transduction efficiency in skeletal muscles varies between AAV serotypes, with the underlying
factors poorly understood. We hypothesized that myofiber-specific tropism differs between AAV serotypes.
Methods: We developed a quantitative histology procedure and generated myofiber pattern maps for four myosin
heavy chain (MyHC) isotypes. We compared myofiber pattern maps between AAV6 or AAV9 injected tibialis anterior
muscle in mice. We correlated MyHC expression with AAV-derived green fluorescence protein (GFP) expression
using statistical models.
Results: We found that MyHC-2x expressing myofibers display a significantly higher preference for AAV
transduction, whereas MyHC-2b expressing myofibers negatively correlated with AAV transduction. In addition,
we show that AAV9-mediated transduction is enriched in myofibers expressing MyHC-1 and MyHC-1/2a. Moreover,
AAV9-mediated transduction can predominantly be predicted by the expression of MyHC isotypes. In contrast,
AAV6 transduction can be predicted by myofiber size but not by myofiber types.
Conclusions: Our findings identify differences between AAV6 and AAV9 for myofiber-type preferences, which could
be an underlying factor for mosaic transduction of skeletal muscle. Adjusting AAV serotype for specific muscle
conditions can therefore improve transduction efficacy in clinical applications.
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Background
Adeno-associated viruses (AAV) have been successfully
engineered as gene-delivery vectors for efficient transduc-
tion of post-mitotic cells including skeletal muscles [1].
AAV-derived transgene expression is sustainable, consist-
ent over time, and safe in preclinical applications [2].
Ongoing innovations in AAV vector engineering have
further improved their suitability for application in clinical
trials. Over the past decade, several AAV serotypes with
variable tropism have been developed for superior trans-
duction [3, 4], and most of these have been suggested for
use in skeletal muscle transduction [5]. However, three
AAV serotypes, AAV1, AAV6, and AAV9, are mostly used
in pre-clinical studies [2]. Broad tropism, safety, and high
transduction efficiency are among the main considerations
for serotype utilization. However, this is not fully exploited
and results are not always consistent between studies. For
example, in dogs, AAV1 tropism is broader and not
specific to skeletal muscles as compared to AAV9 [6], but
AAV9 tropism in mice was suggested to be broader than
AAV6 or AAV1 [2, 4]. Furthermore, in mice, AAV6 shows
more resistance to proteasome-mediated degradation
compared with AAV1 [7]. Elucidating tissue-specific trop-
ism of AAV serotypes is therefore necessary to understand
transduction efficiency and targeted application in the
changing environment of a tissue like skeletal muscle.
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Muscle tissue is composed of contractile fibers (also
known as myofibers) that can be generally subdivided
into four interchangeable types, marked by the expres-
sion of four myosin heavy chain (MyHC) isotypes:
MyHC-2b, MyHC-2x, MyHC-2a, and MyHC-1 [8–10].
The distribution of the myofiber types changes dynamic-
ally to accommodate alterations in muscle function and
metabolism [11]. Moreover, in muscular disorders, a
switch in myofiber types is accompanied by muscle
disuse and atrophic conditions [12, 13]. However, prefer-
ence of AAVs for myofiber types and its contribution to
overall transduction efficiency has not been thoroughly
investigated. We studied myofiber-type preference in
mouse tibialis anterior (TA) muscle following AAV6 or
AAV9 intramuscular administration. We found that
while AAV6 transduced smaller myofibers with a higher
preference for MyHC-2x expressing myofibers, AAV9
transduction can be determined by MyHC expression.
We therefore suggest that myofiber types of skeletal
muscle can play a role in the selection of AAV serotypes
for effective transduction and treatment.
Methods
AAV vectors
The AAV expression pTRCGW vector containing
inverted terminal repeats (ITRs) of AAV2, EGFP (named
here green fluorescence protein (GFP)) cDNA under
control of the cytomegalovirus (CMV) promoter and poly-
adenylation signal of the simian virus 40, and the wood-
chuck post-transcriptional regulatory element (WPRE)
was used for AAV production. AAV6 and AAV9 particles
expressing the same vector were generated and purified as
described before [14]. Briefly, for each AAV serotype, six
15-cm petri dishes containing 12.5 × 106 HEK 293 T cells
were transfected with branched polyethyleneimine (Sigma,
St Louis, MO, USA). For AAV6, pTRCGW was co-
transfected with the serotype-specific helper plasmid (ratio
3:1, total DNA 50 μg/plate). For AAV9, pTRCGW was co-
transfected with the helper plasmid pAdΔF6 and the
serotype-specific helper plasmid (ratio 2:2:1, total DNA
62.5 μg/plate). Helper plasmids for AAV6 were kindly pro-
vided by JA Kleinsschmidt [15] and for AAV9 by JM
Wilson [16]. Transfected cells were grown in 20 ml
Iscove’s modified Eagle’s medium with 10 % fetal calf
serum (FCS), glutamate, and penicillin/streptomycin (Invi-
trogen, Carlsbad, CA, USA) for 2 days. Cells were lysed
and virus particles were harvested and purified using a
density gradient of Iodixanol as published before [17] with
slight modifications. Briefly, cells containing virus particles
were harvested into phosphate-buffered solution (PBS)
and lysed by doing freeze-thaw in dry ice/ethonal for three
times in the presence of DNAse (10 mg/ml). The lysate
was incubated for an hour at 37 °C and centrifuged at
4000g for 30 min. The supernatant containing AAVs was
then underlaid with a gradient of 15, 25, 40, and 60 %
Iodixanol in water (Nycomed Pharma AS, Oslo, Norway) in
Beckman Quick-Seal Polyallomer tube using a pasteur pip-
ette. The tube was sealed and placed into a NVT90 rotor
(Beckman Instruments) and centrifuged at 69,000 rpm for
70 min at 16 °C. Fractions of approximately 3 ml of the
Iodixanol gradient (1 ml of 60 % layer and 2 ml of 40 %
layer) were collected from the bottom of the tube. The
AAV derived from the Iodixanol gradient was further
diluted 10 times with PBS, pH 7.5, to reduce the viscosity
of the Iodixanol, and was subsequently concentrated
using Amicon Ultra-15 centrifugal filter units (Milli-
pore, Amsterdam, The Netherlands). The removal of
cellular impurities in AAV stocks were further con-
firmed using protein gel electrophoresis and electron
microscopy as described before [17]. Virus titers were
determined by quantitative PCR using a primer-set
targeting the WPRE sequence of the expression cas-
sette and indicated as genomic copies per unit vol-
ume (gc/ml) [14]. Genomic copies therefore represent
only particles containing the expression cassette. All
AAV stocks were kept at −80 °C prior to injections.
Mouse strain and AAV particles injection
Male C57BL/6Jico mice of 7–8-week old were purchased
from Jackson laboratories. After 1 week of acclimatization,
AAV6 or AAV9 particles (2.13 × 1010 gc in 50 μl PBS; indi-
cated in the text 2 × 1010 gc) were intramuscular injected
into either left or right tibialis anterior muscles. Addition-
ally, AAV9 (2.13 × 1011 gc; indicated in the text 2 × 1011 gc)
and PBS control were injected into right or left TA muscles,
respectively. Five mice were used per injection set. Injec-
tions were carried out under general anesthesia using 2 %
isoflurane (Pharmachemie BV, Haarlem, The Netherlands).
Mice were housed in ventilated cages with sterile bedding,
water, rodent food, and air in DM-III containment level.
Experiments were carried out in accordance with the
Animal Research: Reporting of In Vivo Experiments (AR-
RIVE) guidelines [18]. An animal research protocol
[#13113] was approved by the Institutional Animal Ethical
Committee (DEC), Leiden University Medical Center,
Leiden, the Netherlands.
In vivo fluorescence imaging, muscle collection, in vitro
imaging, and image quantification
After AAV injection, mice were imaged on a weekly basis
for a period of 4 weeks using the Maestro™ in vivo fluores-
cence imaging system (Xenogen product from Caliper Life
Sciences, Hopkinton, Massachusetts, USA) according to
the manufacturer’s instructions. Mice were anesthetized
with a continuous flow of 2 % isoflurane prior to imaging,
and GFP fluorescence was acquired with an acquisition
time ranging from 30 to 90 s depending upon the fluores-
cent signals from the AAV-injected TA muscles.
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Four-week post-injection mice were sacrificed by
cervical dislocation, and TA muscles were collected and
immersed in liquid nitrogen cold isopentane for about
30–45 s and then stored at −80 °C for further processing.
Transverse cryosections of 10-μm thick were made with a
cryostat (Leica CM3050S) and pasted on superfrost plus
glass slides (Menzel-Gläser; Thermo scientific) from four
alternating parts across the muscle (Additional file 1:
Figure S1). Additional tissue from the intervening areas
was used for RNA isolation, ensuring representation of
the whole muscle during data collection. Histological ana-
lyses of the muscle sections included hematoxylin and
eosin staining [19] and immunofluorescence for myofiber
typing. The untreated cryosections were directly incubated
with a primary antibody to Laminin (1:1000; ab11575,
Abcam). When indicated, a supernatant of hybridoma 6H1
(1:5, Developmental Studies Hybridoma Bank (DSHB),
USA), detecting MyHC-2x was co-incubated. These anti-
bodies were detected with secondary anti-rabbit-alexa-647
and anti-mouse-alexa-546 (Molecular Probes, Invitrogen).
A mixture of monoclonal antibodies to MyHC-1, MyHC-
2a, and MyHC-2b isotypes (hybridoma BA-D5, SC-71 and
BF-F3, respectively (DSHB)), conjugated with alexa-350,
alexa-594, and alexa-488, respectively was generated as
describe before [8]. Antibody production from hybridomas
and fluorophore conjugation was carried out as described
earlier [10]. All antibody incubations were carried out in
PBS containing 0.05 % tween (PBST) and 5 % dry milk, and
washes were carried out with PBST. Slides were mounted
with Aqua Polymount (Polyscience). Incubation with only
anti-mouse conjugated secondary was carried out to ex-
clude nonspecific binding to GFP positive myofibers. Im-
aging of GFP was carried out in untreated sections that
were directly mounted with Polymount containing 4′,6-dia-
midino-2-phenylindole (DAPI). Imaging was carried out
with either DM5500 or TCS-SP5 (confocal) microscopes
(Leica) using LAS AF software versions: 2.3.6 (DM5500)
and 2.5.1.6757 (TCS-SP5), respectively.
Image quantification was carried out with ImageJ, ver-
sion 1.48 [20]. Per myofiber mean fluorescence intensity
(MFI) and cross-sectional area (CSA) were documented
after segmenting sections based on Laminin staining.
Subsequently, MFI values were corrected for background
and normalized for a fluorophore constant, which was
determined from unbound fluorochrome per microscope
and camera combination: (DM 5500: 430 nm= 0.735;
488 nm= 0.067; 596 nm= 0.172 and SP5: 488 nm= 0.003;
546 nm= 3.90).
Quantitative RT-PCR
RNA isolation and RT-qPCR were performed as de-
scribed previously [21]. Messenger RNA (mRNA) fold
changes were calculated after normalizing to the average
CT values of Hprt and Gapdh housekeeping genes and
to the mean of PBS-injected TA muscles. Primers used
in this study are listed in Additional file 1: Table S1.
Statistical analyses
Fold changes and statistical significance of mRNA were
determined with the Student’s t test in GraphPad Prism
version 6.02. P values <0.05 were considered statistically
significant. Statistical analyses of myofibers were carried
out on natural log transformed values of the MFI
(normalized to the fluorophore constant). A correlation
between MFI of GFP and MyHC isotypes was assessed
in a multivariate linear regression model with GFP MFI
as a dependent variable and MyHC MFIs as independent
variables. In a second multivariate model, CSA was
added into the first model as an independent variable.
Both models were stratified based on AAV serotypes. In
addition, Pearson correlation was used to assess correla-
tions between CSA, GFP, and the MFI of each MyHC
isotype. Analyses were performed with IBM SPSS Statis-
tics version 20.0.
Results
Enhanced transduction efficiency and inflammatory
response by AAV6
To compare transduction efficacy identical doses (2 × 1010
gc) of AAV6 or AAV9 and a higher dose of AAV9 (2 ×
1011gc), particles containing the same expression vector
were injected into TA muscles. A contralateral PBS injec-
tion was used as a control. GFP expression was used to
assess transduction efficiency in living animals on weekly
basis. In all animals, the accumulation of GFP mean fluor-
escence intensity (MFI) was stabilized 3 weeks post-
injection (Additional file 1: Figure S2), and the GFP signal
was predominantly localized in TA muscles (Fig. 1a,
Additional file 1: Figure S3). Mice were sacrificed at 4 weeks
post-injection, and TA muscles were collected for the ana-
lyses. The GFP MFI measured from the AAV6 injected
muscle was higher compared to that found in the AAV9
injected muscles with the same particle dose (Fig. 1a, b).
Higher efficacy of AAV6 was also confirmed by GFP
mRNA analysis (Fig. 1c). A 10-fold higher dose of AAV9
elevated the GFP MFI and mRNA as compared with AAV9
lower dose (Fig. 1b–d). In the AAV6 injected muscles, we
observed remarkably high number of nucleated cells within
the tissue, suggesting an activation of inflammatory re-
sponse (Fig. 1e). Indeed, the expression of four macrophage
markers (CD68, MAC2, F4/80, MCP-1) and four inflamma-
tory markers (IL-6, IL1-R, NF-kB, and TNFa) was elevated
in AAV6 as compared to PBS injected muscles (Fig. 1f).
This observation is consistent with previous studies that
suggest an induction of inflammatory responses by AAV6
[5, 22]. In contrast, in the high-dose AAV9-injected mus-
cles, up-regulation of inflammatory genes was limited to






Fig. 1 (See legend on next page.)
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IL6 (Fig. 1f), suggesting that inflammation in TA muscle is
not activated by AAV9 administration.
Inflammation in muscles is associated with damaged
muscles as characterized by leaky membranes and cen-
tral nuclei [11]. In the AAV6-injected muscles, we found
an increase in myofibers containing central nuclei (Fig. 1e
and Additional file 1: Figure S4). About 3 % of myofibers
in AAV6-injected TA muscles have central nuclei, but in
the AAV9-injected muscles, the percentage of central
nuclei was not different from the PBS injected muscles
(Fig. 1g). Moreover, in the AAV6 but not in AAV9-
injected muscles, we found regions with damaged myofi-
bers and dispersed GFP fluorescence across myofibers
(Additional file 1: Figure S5). This dispersed GFP fluor-
escence differed from a fiber-restricted localization of
GFP in the AAV9-injected muscles (Fig. 1d).
Preferential transduction of specific myofiber types by
AAV6 and AAV9
Histological analysis revealed mosaic GFP expression in
both AAV6- and AAV9-injected muscles. We investigated
whether myofiber types could underpin differences in
muscle transduction. We first assessed a simple correlation
between GFP MFI and myofiber CSA. In both AAV6- and
AAV9-transduced muscles, we found a negative correlation
between GFP and myofiber CSA (Additional file 1: Table
S2A). This negative correlation could partly be explained
by higher concentration of GFP fluorescence in smaller
myofibers. However, the correlation between CSA and GFP
was much lower in AAV9-injected muscles compared with
that of AAV6 (−0.39 and −0.55, respectively). Myofiber
CSA was also correlated with the expression levels of
MyHC isotypes (Additional file 1: Table S2A). We therefore
further assessed whether AAV-mediated gene expression is
affected by myofiber types; we correlated GFP expression
per myofiber with the expression levels of myofiber types
(Additional file 1: Figure S6). MFI of both GFP and each of
MyHC fluorophores were measured per myofiber (Fig. 2a).
Using a Pearson correlation, we found a negative correl-
ation between MyHC-2b expression and GFP in both
AAV6- and AAV9-injected muscles, whereas MyHC-2a
expression positively correlated with GFP. The expression
of MyHC-1 positively correlated with GFP in only AAV9-
transduced muscles (Additional file 1: Table S2B). Plotting
MFI of all four fluorophores per myofiber against GFP MFI
of corresponding myofibers showed a negative preference
of GFP expression in MyHC-2b expressing myofibers
(Fig. 2b). Furthermore, we found a strong correlation be-
tween MyHC-2a and MyHC-1 expression in these muscles,
but not between MyHC-2b and either MyHC-2a or
MyHC-1 (Additional file 1: Table S2C). These analyses sug-
gest hybrid myofibers co-expressing MyHC-1 and MyHC-
2a; however, hybrid myofibers expressing MyHC-2b and
either MyHC-2a or MyHC-1 were not identified in TA
muscles.
Since we found hybrid myofibers co-expressing MyHC
isotypes (Fig. 2b), we next assessed the contribution of each
MyHC isotype to GFP expression using a multivariate
model. In the AAV6-transduced muscles, a weak positive
correlation was found between MyHC-2a expression and
GFP (regression coefficient (β) = 0.25; P = 0.007; Table 1,
Model 1). In the AAV9-transduced muscles, however,
MyHC-2a expression negatively correlated with GFP
whereas MyHC-1 positively correlated with GFP (β = −0.38,
P < 0.001; β = 0.80, P < 0.001; respectively, Table 1, Model
1). The negative correlation between MyHC-2b and GFP
remained unchanged in the multivariate model (Table 1,
Model 1). As we found a correlation between GFP and
CSA (Additional file 1: Table S2A), we then added CSA as
an additional variable into the multivariate model. Surpris-
ingly, in the AAV6-transduced muscles, only the CSA
remained significant (Table 1, Model 2) whereas, in the
AAV9-transduced muscles, a strong correlation between
GFP expression and the aforementioned MyHC isotypes
persisted (Table 1, Model 2). Scatter plots between the
observed GFP and the GFP calculated from the multivariate
models (predicted GFP) showed that in the AAV6- but not
AAV9-transduced muscles, GFP MFI prediction was im-
proved by threefold when CSA was added to the model
(Table 1 and Fig. 2c). Together, these data suggest that
AAV9-mediated transduction is determined by myofiber
types whereas AAV6 transduction is determined primarily
by myofiber size.
The MFI distribution plots (Fig. 2b) suggest that GFP
positive myofibers are enriched in the negatively stained
population of myofibers. In this staining protocol, the
(See figure on previous page.)
Fig. 1 Intramuscular transduction efficiency and inflammatory responses by AAV6 and AAV9 serotypes. Identical dose of AAV6 or AAV9 particles
(2 × 1010 gc) or AAV9 particles (2 × 1011 gc) and PBS control were injected into TA muscles. a Images of living mice show GFP in TA muscles
4 weeks post-injection. b GFP mean fluorescent intensity in TA muscles (N = 5). c GFP mRNA expression in the injected TA muscles (N = 5). CT
values are normalized to Hprt and Gapdh housekeeping genes and to PBS-injected muscles. d Muscle histology of GFP expression in cross
sections. Upper row shows bright field and DAPI staining of the nuclei. Images in the lower row were taken with a GFP filter and DAPI. Scale bar is
50 μm. e Muscle histology of HE staining. White arrows point to area with macrophage infiltration, and black arrows show myofibers with central
nucleation. Scale bar is 200 μm. f Inflammatory gene expression in the AAV6- or AAV9-injected muscles (2 × 1011 gc) (N = 4). CT values are normalized
to Hprt and Gapdh housekeeping genes and to PBS-injected muscles. All eight genes are significantly up-regulated in AAV6 muscles, but only IL6 is
up-regulated in AAV9. g Bar chart shows the proportion of myofibers with central nuclei. The total number of fibers is indicated above each bar
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negatively stained myofibers are regarded as MyHC-2x
isotype expressing myofibers [8]. To assess whether GFP
positive myofibers are indeed MyHC-2x expressing myo-
fibers, we stained muscle sections with an antibody to
MyHC-2x isotype (Fig. 3a). Primary antibody missing
control was performed to exclude a possibility of prefer-
ential adherence of the conjugated secondary antibody
alexa-546 with GFP positive myofibers (Additional file 1:
Figure S7). A strong positive correlation was found
between MyHC-2x expression and GFP in myofibers
from AAV6- or AAV9-transduced muscles (Pearson cor-
relation: P < 0.001) (Fig. 3b). Interestingly, a better fitness
(>2-fold) to the linear regression line was found in the
AAV9 muscles as compared with AAV6 (R2 = 0.48 or
0.23, respectively) (Fig. 3b). Commutative correlation
plot of GFP MFI also confirmed better fitness to the
regression line (R2) in AAV9-transduced myofiber com-
pared with AAV6 fibers (Fig. 3c). These data suggest that
both AAV6 and AAV9 show transduction preference for
MyHC-2x expressing myofibers with a higher preference
for AAV9.
Discussion
In the last couple of decades, several AAV serotypes have
been developed for effective gene delivery into various
tissues including skeletal muscle with AAV vectors emer-
ging as promising vehicles in clinical trials for monogenic
musculoskeletal diseases including Duchenne and limb-
girdle muscular dystrophy [23, 24]. Muscle tissue is com-
posed of different but interchangeable myofibers, which
determine muscle contraction and tissue stabilization.
Here, we show that the transduction of myofiber types
differs between AAV serotypes, using AAV6 and AAV9 as
an example. The same expression vector was packaged in
AAV6 and AAV9, and a standard protocol of virus parti-
cles generation and purification was used for both sero-
types. This ensures that all observed differences are
attributed to differences in AAV serotype. Consistent with
previous studies, we found that AAV transduction of skel-
etal muscle results in a mosaic pattern [25–27]. Here, we
found that the preferential transduction of myofiber types
may explain the observed mosaic transduction by AAVs.
A previous study has assessed correlation of AAV trans-
duction with myofiber types using CMV-mediated lacZ as
a reporter gene. Although this study found preferential
transduction of the TA muscle over soleus, correlation of
reporter gene expression with MyHC isotypes was un-
clear. The authors suggested that their procedure was
limited by quantitative measurements [25]. We employed
a quantitative histology procedure for myofiber typing by
combining the antibodies to four MyHC isotypes. More-
over, in contrast to previous studies that used visual
assessment for myofiber types [25, 26], our assessment of
myofiber types is based on measurement of the MFI of
each myofiber type. This quantification of MyHC isotypes
expression per myofiber enables us to apply prediction
models and determine the contribution of each myofiber
type to transgene expression. We found significant differ-
ences between AAV6 and AAV9 for their transduction
preferences to myofiber types. Myofibers expressing
MyHC-2b isotype poorly express GFP that was derived by
either AAV6 or AAV9. In our cassette, GFP was expressed
under CMV promoter; thus, we cannot exclude the possi-
bility of suboptimal activity of CMV promoter in MyHC-
2b myofibers. However, previous studies showed that the
CMV promoter does not discriminate between myofiber
Table 1 MyHC protein expression correlates with AAV9- but not with AAV6-mediated transduction
Model 1: Myofiber types Model 2: Myofiber types and CSA
AAV6 (N = 185) AAV9 (N = 202) AAV6 (N = 185) AAV9 (N = 202)
β for GFP (SE) P value β for GFP (SE) P value β for GFP (SE) P value β for GFP (SE) P value
MyHC-2b −0.12 (0.07) 0.070 −0.38 (0.06) <0.001 −0.07 (0.06) 0.23 −0.27 (0.07) <0.001
MyHC-2a 0.25 (0.09) 0.007 −0.24 (0.07) <0.001 −0.15 (0.10) 0.12 −0.38 (0.08) <0.001
MyHC-1 −0.38 (0.28) 0.170 0.80 (0.13) <0.001 −0.03 (0.25) 0.91 0.84 (0.12) <0.001
Linear regression analyses were performed including mean fluorescent intensities (MFI) for GFP as a dependent variable. In model 1, MFIs of myofibers expressing
MyHC-2b, MyHC-2a, and MyHC-1 isotypes were included as independent variables. In model 2, cross-sectional area (CSA) of the myofibers was additionally
included as an independent variable. Models were stratified for AAV6 and AAV9. Beta of the regression analysis and standard errors (SE) are provided
(See figure on previous page.)
Fig. 2 Analysis of GFP and myofiber-type correlation in AAV6- or AAV9-transduced muscles. a Images of representative sections after
immunohistochemistry with four antibodies to MyHC isotypes (staining of each MyHC isotype separately is shown in Additional file 1:
Figure S5) and GFP fluorescence in a consecutive section. Examples of matching myofibers are marked with arrowheads. Scale bar in
50 μm. b Plots show mean fluorescent intensity (MFI) distribution of MyHC isotypes and GFP within a myofiber (NAAV6 = 188 fibers; NAAV9
= 202 fibers); GFP in light green, MyHC-2b in dark green, MyHC-2a in red, and MyHC-1 in blue. Myofiber types that predominantly express
MyHC-2b, MyHC-2a or MyHC-2a/1, and negatively stained myofibers are schematically indicated. c Scatter plots show the distribution of
observed GFP MFI versus predicted GFP in AAV6 (in green) or AAV9 (in blue) conditions. Linear regression and fitness (R2) are depicted in
green or blue to AAV6 or AAV9, respectively. Predicted GFP is calculated using MyHC-2b, MyHC-2a, and MyHC-1 isotypes are variable (left)
or MyHC-2b, MyHC-2a, and MyHC-1 isotypes and CSA (right)
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types [28, 29]. Additional studies with different promoters
and reporters could clarify this potential concern. We sug-
gest that not all myofiber types are readily permissive for
AAV. In agreement with this hypothesis, a recent study
demonstrated that AAV does not transduce satellite cells,
the muscle stem cells within a muscle tissue [30]. In con-
trast to myofibers expressing MyHC-2b, myofibers ex-
pressing MyHC-2x isotype were preferentially transduced
by both AAV6 and AAV9. Analysis of MyHC-2x was ab-
sent from a study that investigated the effect of AAV
transduction between myofiber types [25]. Although, some
receptors for AAV9 have been identified [31–33], but the
molecular basis for AAV transduction and cell type speci-
ficity is still poorly understood. Elucidation of AAV sero-
type and myofiber specificity should be addressed in
future studies, which should include screening of add-
itional muscles expressing MyHC isotypes at different ra-
tios and hybrid myofibers in different disease conditions.
This will hopefully lead to develop more effective gene
therapy strategies using AAV vectors.
Using the prediction model that includes myofiber
types and CSA, we show that a correlation between GFP
MFI and myofiber types was insignificant in the AAV6-
transduced muscles but remained significant in the
AAV9-transduced muscles. Importantly, addition of CSA
to this model significantly improved the prediction of
GFP MFI in AAV6- but not in AAV9-transduced mus-
cles. Together, this suggests that AAV9-mediated trans-
duction is predominantly determined by myofiber types
whereas AAV6 transduction is determined primarily by
myofiber size. Variations in transduction efficiency be-
tween AAV serotypes and different muscles are not fully
understood. The TA muscle is more effectively trans-
duced by AAV9 vector compared to the soleus muscle
[26]. However, AAV6 is more effective for soleus trans-
duction over AAV2 [25]. AAV1 transduction in dog
models for muscular diseases seems to be more effective
compared to mice [6]. Recently, AAV8 has also been
suggested as an improved vehicle for transduction of
muscle tissues [34]. Future studies should include testing
of transduction efficiency of various serotypes in differ-
ent muscles of multiple species, and this could result in
an atlas of AAV serotypes and myofiber specificity for
more effective utility of AAV-mediated gene therapy.
Conclusions
In summary, we report that AAV-mediated myofiber
transduction differs between AAV serotypes. Moreover,
AAV serotypes show preferential transduction for myofi-
ber types. We developed a quantitative histology proced-
ure for myofiber typing, which allows us to assess AAV-
mediated transduction using statistical prediction models.
Using these models, we show that in skeletal muscle, fast-
twitch myofiber expressing MyHC-2b isotype is poorly
transduced, whereas those expressing MyHC-2x isotype are
preferentially transduced by both AAV6 and AAV9. We
further show that in wild-type mice, transduction of myofi-
bers by AAV9 serotype can predominantly be explained by
Fig. 3 Analysis of MyHC-2x expression in GFP expressing myofibers. a Images of representative sections after immunohistochemistry with anti-MyHC-2x
antibody and GFP fluorescence in the corresponding myofibers from a consecutive section. Examples of matching myofibers are marked with arrowheads.
Scale bar is 50 μm. b Scatter plot shows a correlation between MFI of MyHC-2x and GFP in AA6 (in blue)- and AAV9 (in green)-transduced myofibers.
Linear regression lines and fitness to the regression line (R2) are indicated. c. Commutative correlation plot of GFP MFI in AA6 (in blue)- and AAV9
(in green)-transduced myofibers. Fitness to the regression line (R2) and P value Kolmogorov–Smirnov (KS) test are indicated
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myofiber type, whereas transduction by AAV6 serotype
can be explained by myofiber size, but not by myofiber
type. Future studies should expand these results in muscu-
lar disease models, and such studies may open a new dis-
cussion to the choice of AAV serotype and cell type
specificity for AAV-mediated transduction in clinical ap-
plications. We suggest that understanding of AAV tropism
at myofiber type levels will improve transduction efficacy
and specificity for clinically interesting muscles.
Additional file
Additional file 1: A pdf file containing two supplementary tables
(S1–2) and five supplementary figures (S1–5) are included as an
Additional file 1. Table S1 contains primer sequences used in this
study. Table S2 contains myofiber-based univariate correlations. Figure
S1 shows schematic summary of methodology. Figure S2 shows GFP
fluorescence in AAV-injected TA muscles. Figure S3 shows GFP fluorescence
in all 10 AAV- or PBS-injected mice at 4 week post-injection. Figure S4
indicates myofiber damage in AAV6-transduced TA muscles. Figure S5 shows
immunohistochemistry with antibodies to MyHC type-2b, MyHC type-2a, and
MyHC type-1 and to laminin in AAV6- and AAV9-injected animals.
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